Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Wheeler

Showing results (271-280 of 454) with videos related to

Pageof 46
Sort By:
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialHiddo J L Heerspink, Niels Jongs, Glenn M Chertow, et al.
Environmental Science & Technology|August 20, 2013
Environmental determinants of polychlorinated biphenyl concentrations in residential carpet dustCurt T DellaValle, David C Wheeler, Nicole C Deziel, et al.
Occupational and Environmental Medicine|November 17, 2012
Inside the black box: starting to uncover the underlying decision rules used in a one-by-one expert assessment of occupational exposure in case-control studiesDavid C Wheeler, Igor Burstyn, Roel Vermeulen, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Quételet (body mass) index and effects of dapagliflozin in chronic kidney diseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
Trials|October 15, 2025
A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trialToby J L Humphrey, Fergus J Caskey, David C Wheeler, et al.
Journal of the American Society of Nephrology : JASN|May 17, 2018
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-AnalysisAmarnath Marthi, Killian Donovan, Richard Haynes, et al.
Clinical Kidney Journal|February 11, 2022
The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysisAlexander D Lalayiannis, Charles J Ferro, David C Wheeler, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 16, 2024
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression TrialsRobert A Fletcher, William G Herrington, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2016
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)Natalie Staplin, Richard Haynes, William G Herrington, et al.
Pageof 46

Showing results (271-280 of 454) with videos related to

Sort By:
Pageof 46
The Lancet. Diabetes & Endocrinology|October 7, 2021
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialHiddo J L Heerspink, Niels Jongs, Glenn M Chertow, et al.
Environmental Science & Technology|August 20, 2013
Environmental determinants of polychlorinated biphenyl concentrations in residential carpet dustCurt T DellaValle, David C Wheeler, Nicole C Deziel, et al.
Occupational and Environmental Medicine|November 17, 2012
Inside the black box: starting to uncover the underlying decision rules used in a one-by-one expert assessment of occupational exposure in case-control studiesDavid C Wheeler, Igor Burstyn, Roel Vermeulen, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 14, 2025
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome TrialsMegumi Oshima, Luke Buizen, Niels Jongs, et al.
Diabetes, Obesity & Metabolism|January 5, 2022
Quételet (body mass) index and effects of dapagliflozin in chronic kidney diseaseGlenn M Chertow, Priya Vart, Niels Jongs, et al.
Trials|October 15, 2025
A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trialToby J L Humphrey, Fergus J Caskey, David C Wheeler, et al.
Journal of the American Society of Nephrology : JASN|May 17, 2018
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-AnalysisAmarnath Marthi, Killian Donovan, Richard Haynes, et al.
Clinical Kidney Journal|February 11, 2022
The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysisAlexander D Lalayiannis, Charles J Ferro, David C Wheeler, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 16, 2024
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression TrialsRobert A Fletcher, William G Herrington, Rajiv Agarwal, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 28, 2016
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)Natalie Staplin, Richard Haynes, William G Herrington, et al.
Pageof 46